Anemia and Red Blood Cells Transfusion in Oncological Surgery

• Conditions: Surgery; Oncology; Anemia

• Registration Number: NCT04101240
• Lead Sponsor: University Hospital, Brest

Brief Summary

Oncologic patients experience anemia and anemia is associated with poor prognosis. Transfusion is associated with adverse events, and equipoise remains on the optimal transfusion strategy in oncologic patients in surgical setting. The primary objective of this study is to determine the impact of anemia and red blood cells (RBC) transfusion on post-operative complications and mortality.

Detailed Description

Between 36 and 75% of oncologic patients experience anemia and anemia is associated with poor prognosis. Up to 40% of surgical oncologic patients receive red blood cells (RBC). However, transfusion is associated with adverse events, and equipoise remains on the optimal transfusion strategy in oncologic patients in surgical setting. The primary objective of this study is to determine the impact of anemia and red blood cells (RBC) transfusion on post-operative complications and mortality. This is a retrospective, single center study. All adults admitted to the intensive care unit (ICU) after oncologic surgery within the study period are eligible.

Study Timeline

• Study Start: 2019-02-07
• Status Verified: 2019-09
• Study First Submitted: 2019-09-23
• Study First Submitted QC: 2019-09-23
• Last Update Submitted: 2019-09-23
• Study First Posted: 2019-09-24
• Last Update Posted: 2019-09-24
• Primary Completion: 2019-11-30
• Study Completion: 2019-11-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Surgery for cancer
• Admission to intensive care

Exclusion Criteria

• no consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of mortality or any respiratory, cardiac, renal, thromboembolic, infectious and/or hemorrhagic post operative complications	30 DAYS (hospital discharge)	mortality or any respiratory, cardiac, renal, thromboembolic, infectious and/or hemorrhagic post operative complications

Trial Locations

Locations (1)

CHRU de Brest, hôpital de la Cavale Blanche; 🇫🇷 Brest, France